x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:09:41

Aulos Bioscience presented phase 2 data at SITC for...

BiotechTV - News ·

2025/11/08

CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class.

en-us

00:08:34

Enara Bio publicly announced its first cancer...

BiotechTV - News ·

2025/11/08

CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.

en-us

00:11:53

Compugen is standing firm on its belief that TIGIT...

BiotechTV - News ·

2025/11/08

The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.

en-us

00:12:56

Synthekine presented data at SITC on its α/β-IL-2...

BiotechTV - News ·

2025/11/08

Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β receptors in this case. In addition to the phase 1a/1b that is reading at SITC, Synthekine has already started a randomized phase 2 study.

en-us

00:09:18

Marengo Therapeutics has presented data at ESMO and...

BiotechTV - News ·

2025/11/08

CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.

en-us

00:08:01

Brain shuttle technologies have been in the news a...

BiotechTV - News ·

2025/11/08

She and her colleagues at inThought Research recently published a report summarizing the brain shuttle technology research landscape in the biotech sector.

en-us

00:13:46

Menlo Ventures published a report showing that the...

BiotechTV - News ·

2025/11/05

Menlo Ventures Partner, and co-author of the report, Derek Xiao talks about how AI is improving the P&L of health systems and helping with staffing shortages. Medical documentation, billing and scribing are the biggest areas of adoption today, while patient engagement and the post acute relationship are emerging as next to be impacted.

en-us

00:07:53

BIO-Europe 2025: Spain based ARTHEx Biotech is a...

BiotechTV - News ·

2025/11/04

CEO Frédéric Legros walks us through the science and explains why he believes ARTHEx has a unique approach compared to others we have seen in the field. The company raised an $87M series B in September.

en-us

00:08:03

BIO-Europe 2025: Sparrow Pharmaceuticals raised a...

BiotechTV - News ·

2025/11/04

CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so could be beneficial for treatment-resistant T2D patients.

en-us

00:08:02

BIO-Europe 2025: Topas Therapeutics is delivering...

BiotechTV - News ·

2025/11/04

CEO Hugo Fry describes the scientific idea behind antigenic tolerization, and discusses Topas' recent PoC data that was presented at Digestive Disease Week.

en-us

00:06:43

BIO-Europe 2025: Step Pharma has 'followed the...

BiotechTV - News ·

2025/11/04

He explains the story of this enzyme and the biology of how CTPS1 and CTPS2 interact. Step is in the clinic in lymphoma and solid tumors, and recently raised a €38 series C.

en-us

00:10:52

BIO-Europe 2025: Barcelona based Connecta...

BiotechTV - News ·

2025/11/04

CEO Jordi Fàbrega and CFO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta.

en-us

00:09:53

BIO-Europe 2025: Switzerland based ReproNovo is...

BiotechTV - News ·

2025/11/03

CEO Jean Marie Duvall describes the company's programs, one focused on male inferitliy and another that may have dual purposes of helping with embryo implantation and adenomyosis. She says to make sure there is a clear commercial path if when you focus on this field.

en-us

00:11:11

BIO-Europe 2025: Anavo Therapeutics is focused on...

BiotechTV - News ·

2025/11/03

CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the company is now disclosing two indications/targets in development.

en-us

00:10:12

BIO-Europe 2025: Herantis Pharma is developing...

BiotechTV - News ·

2025/11/03

CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year.

en-us

00:16:34

BIO-Europe 2025: Valneva's partner Pfizer has been...

BiotechTV - News ·

2025/11/03

Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine.

en-us

00:15:41

Roche will pay Manifold Bio $55M up front, and up to...

BiotechTV - News ·

2025/11/03

Manifold Co-Founders Gleb Kuznetsov and Pierce Ogden explain how Manifold is working on next generation shuttles, which means going beyond transferrin. They discuss the deal, and also Manifold's broader platform of high-throughput, in-vivo discovery work.

en-us

00:09:45

BIO-Europe 2025: ReNewVax CEO Neil Murray believes...

BiotechTV - News ·

2025/11/03

He describes the unmet need for a better vaccine than those already on the market, and says he is looking for a lead investor for a series A at BIO-Europe.

en-us

00:12:51

BIO-Europe 2025: Abivax CEO Marc de Garidel discusses...

BiotechTV - News ·

2025/11/03

He describes the mechanism of the therapy, as well the data and commercial landscape for UC. Plus, how he thinks about combos and business development.

en-us

00:10:41

BIO-Europe 2025: AAVantgarde Bio, which is working on...

BiotechTV - News ·

2025/11/03

CEO Natalia Misciattelli describes the lead programs for Stargardt Disease and Usher 1B Syndrome, and how AAVantgarde is able to solve the problem of delivering genes that are naturally too large for single AAV vectors.

en-us

287 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter